A potential risk to Sun Pharma’s consensus earnings, coupled with its premium valuations are cited as the two important factors behind the downgrade by BofA Securities.
A potential risk to Sun Pharma’s consensus earnings, coupled with its premium valuations are cited as the two important factors behind the downgrade by BofA Securities.